MX2023002979A - Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos. - Google Patents
Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos.Info
- Publication number
- MX2023002979A MX2023002979A MX2023002979A MX2023002979A MX2023002979A MX 2023002979 A MX2023002979 A MX 2023002979A MX 2023002979 A MX2023002979 A MX 2023002979A MX 2023002979 A MX2023002979 A MX 2023002979A MX 2023002979 A MX2023002979 A MX 2023002979A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- estrogen receptor
- crystalline forms
- polymorphic forms
- targeted degradation
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a formas polimórficas de (S)-3-(5-(4-((1-(4-((1R,2S)-6-hidroxi-2-fenil-1,2,3,4-tetrahidron aftalen-1-il)fenil)piperidin-4-il)metil)piperazin-1-il)-1-oxoisoi ndolin-2-il)piperidina-2,6-diona, (Compuesto A), a los métodos de fabricación de estas formas polimórficas y a las composiciones que comprenden estas formas polimórficas. Estas formas polimórficas son útiles en el tratamiento de varias enfermedades, que incluyen, por ejemplo, cáncer de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078225P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050046 WO2022056368A1 (en) | 2020-09-14 | 2021-09-13 | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002979A true MX2023002979A (es) | 2023-04-10 |
Family
ID=78080527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002979A MX2023002979A (es) | 2020-09-14 | 2021-09-13 | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220081416A1 (es) |
| EP (1) | EP4211128A1 (es) |
| JP (1) | JP2023541434A (es) |
| KR (1) | KR20230069144A (es) |
| CN (1) | CN116390916A (es) |
| AR (1) | AR123492A1 (es) |
| AU (1) | AU2021342287A1 (es) |
| BR (1) | BR112023004656A2 (es) |
| CA (1) | CA3194954A1 (es) |
| CL (1) | CL2023000712A1 (es) |
| CO (1) | CO2023004435A2 (es) |
| CR (1) | CR20230162A (es) |
| DO (1) | DOP2023000052A (es) |
| EC (1) | ECSP23027481A (es) |
| IL (1) | IL301155A (es) |
| MX (1) | MX2023002979A (es) |
| PE (1) | PE20231555A1 (es) |
| RS (1) | RS20230288A1 (es) |
| TW (1) | TW202214236A (es) |
| WO (1) | WO2022056368A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102173464B1 (ko) * | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
-
2021
- 2021-09-13 EP EP21787193.8A patent/EP4211128A1/en active Pending
- 2021-09-13 KR KR1020237011950A patent/KR20230069144A/ko unknown
- 2021-09-13 CR CR20230162A patent/CR20230162A/es unknown
- 2021-09-13 AU AU2021342287A patent/AU2021342287A1/en active Pending
- 2021-09-13 CN CN202180070126.4A patent/CN116390916A/zh active Pending
- 2021-09-13 RS RS20230288A patent/RS20230288A1/sr unknown
- 2021-09-13 PE PE2023001149A patent/PE20231555A1/es unknown
- 2021-09-13 TW TW110134024A patent/TW202214236A/zh unknown
- 2021-09-13 WO PCT/US2021/050046 patent/WO2022056368A1/en active Application Filing
- 2021-09-13 AR ARP210102530A patent/AR123492A1/es unknown
- 2021-09-13 US US17/472,847 patent/US20220081416A1/en active Pending
- 2021-09-13 MX MX2023002979A patent/MX2023002979A/es unknown
- 2021-09-13 IL IL301155A patent/IL301155A/en unknown
- 2021-09-13 CA CA3194954A patent/CA3194954A1/en active Pending
- 2021-09-13 JP JP2023516491A patent/JP2023541434A/ja active Pending
- 2021-09-13 BR BR112023004656A patent/BR112023004656A2/pt unknown
-
2023
- 2023-03-13 CL CL2023000712A patent/CL2023000712A1/es unknown
- 2023-03-14 DO DO2023000052A patent/DOP2023000052A/es unknown
- 2023-04-10 CO CONC2023/0004435A patent/CO2023004435A2/es unknown
- 2023-04-14 EC ECSENADI202327481A patent/ECSP23027481A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023004435A2 (es) | 2023-04-27 |
| PE20231555A1 (es) | 2023-10-03 |
| US20220081416A1 (en) | 2022-03-17 |
| WO2022056368A1 (en) | 2022-03-17 |
| RS20230288A1 (sr) | 2023-06-30 |
| AU2021342287A1 (en) | 2023-04-13 |
| ECSP23027481A (es) | 2023-07-31 |
| CR20230162A (es) | 2023-06-02 |
| EP4211128A1 (en) | 2023-07-19 |
| IL301155A (en) | 2023-05-01 |
| JP2023541434A (ja) | 2023-10-02 |
| CL2023000712A1 (es) | 2023-10-20 |
| BR112023004656A2 (pt) | 2023-05-09 |
| TW202214236A (zh) | 2022-04-16 |
| AR123492A1 (es) | 2022-12-07 |
| CN116390916A (zh) | 2023-07-04 |
| DOP2023000052A (es) | 2023-07-31 |
| KR20230069144A (ko) | 2023-05-18 |
| CA3194954A1 (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| ME01571B (me) | Polimorfni oblici 3-(4-amin0-1-0ks0-1, 3-dihidro-izoindol-2-il)-piperidin-2, 6-diona | |
| PL338129A1 (en) | Crystalline form of a derivative of n-phenyl-2-dipyrimidin amine, methods of obtaining same and apllication thereof | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| MX2022011534A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa. | |
| DE60218703D1 (de) | (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer | |
| EA200901514A1 (ru) | Новая сольватная и кристаллическая форма производных карбамоилциклогексана | |
| IT1256282B (it) | Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| WO2007032028A8 (en) | Thiazolinones and oxazolinones and their use as ptp1b inhibitors | |
| NZ587518A (en) | Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide | |
| MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
| MX2011005090A (es) | Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)feni l] piperidina. | |
| MX2023002979A (es) | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos. | |
| JOP20210227A1 (ar) | شكل بلوري من مونوهيدرات 1-(1-أوكسو-1، 2-داي هيدروأيزوكينولين-5-يل)-5-(تراي فلوروميثيل)-n-(2-(تراي فلوروميثيل)بيريدين-4-يل)-1h-بيرازول-4-كربوكساميد | |
| MXPA04006033A (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina. | |
| EA201100696A1 (ru) | 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| TNSN07006A1 (en) | Novel heterocyclic compounds | |
| EA200500191A1 (ru) | Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид | |
| BRPI0517734A (pt) | derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina | |
| PH12018502529A1 (en) | Crystalline form of compound suppressing protein kinase activity, and application thereof | |
| MX2009006528A (es) | Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina. | |
| MX2009010243A (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. | |
| JP2003516975A5 (es) | ||
| MX2022004683A (es) | Metodos de tratamiento de neoplasias hematologicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona. |